World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025
LONDON, October 23, 2015 /PRNewswire/ --
Pharma Wholesaling and Distribution - Now Gain Analysis of Companies, Trends and Revenues to Benefit Your Influence
What does the future hold for drug wholesale and distribution (W&D) services? Discover revenue predictions there to 2025. And explore trends in those services and technologies, assessing prospects and finding opportunities to benefit your work and influence.
In visiongain's new report you gain revenue forecasts at overall world market, submarket, company and national level. That study's purpose is to show what is possible. There you assess potential for expanding revenues. See where that industry's best prospects lie.
Read on, then, to explore activities of distributors and wholesalers of pharmaceuticals, discovering what that business's future could be worth and how it changes.
Forecasts and other analysis to benefit your knowledge of medical distribution systems
Is finding pharma wholesale and distribution information a challenge? Avoid falling behind in knowledge on the supply of medicines. With our data you help your research, analyses and decisions. Also you save time and benefit your reputation for commercial insight.
Besides revenue forecasting, our new investigation shows historical data, growth rates and market shares. That industry changes in 2015 through mergers and acquisitions. So avoid missing out. In our study discover what is happening, helping you stay ahead.
There you find original quantitative and qualitative analyses, exploring business outlooks and developments. You also gain 83 tables, 98 charts and a research interview.
Discover where revenues can increase most. In the following sections you see how our new study benefits your knowledge on the supply chain for human medicines.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Prospects for that world market and submarkets - discover what revenues are possible
Our new report shows revenue to 2025 for the overall world market. It also gives you forecasts for three submarkets for distributing and wholesaling of medicines:
• Original-branded pharmaceuticals - small molecules and biological drugs (biologics)
• Generic prescription drugs (generics)
• Other products related to pharmaceutical supply.
How will the pharmaceutical wholesale and distribution (W&D) market grow? Which parts will prosper most, and why? With our data you assess potential sales and revenue growth.
Our study also discusses what stimulates and restrains storing and distributing of drugs. That analysis helps you identify commercial potentials and consider ways for your business to expand.
You also discover geographical revenue predictions.
Sales potentials for medical wholesale and distribution in leading countries
Developments worldwide expand the pharma W&D market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.
In developed and developing regions, opportunities for drug wholesalers and other medical suppliers will occur from 2015. Pharmacies also stand to gain. See where, why and how.
Our report shows you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC nations).
There you discover progress and outlooks. You assess the W&D industry's future, seeing developments and finding their meaning.
Our analysis shows that highest revenue growth to 2025 will occur in developing countries. Developed markets will expand too. You investigate, also finding top companies' potentials.
Sales forecasting and other analysis for leading pharma intermediaries
How will prominent companies perform to 2025? Our work shows you individual revenue forecasts for 10 wholesalers and distributors, including these firms:
• McKesson
• Cardinal Health
• AmerisourceBergen
• Walgreens Boots Alliance
• MEDIPAL HOLDINGS
• The PHOENIX Group
• SINOPHARM
• Alfresa Holdings
• Suzuken
• Shanghai Pharmaceutical Holdings.
With our sales predictions you assess top organisations, seeing activities, results, changes and outlooks. You find what is happening, understanding trends, competition, challenges and opportunities.
That way you explore the industry's future, discovering progress and finding what it means. Our study explains the issues affecting that industry's present and future.
Forces and changes affecting the supply of pharmaceuticals through distribution networks
Our report explains issues, events and shifts affecting that industry and market from 2015, including these influences:
• Roles of medical wholesalers - activities, changes and prospects
• Revenues, costs and profits - find results, opportunities and sales potentials
• Direct-to-pharmacy (DTP) activities - assess how those developments affect suppliers, clients and the W&D market
• Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
• Technologies and services - progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, payers and patients
• Forward buying, fee-for-service systems and the rise of retail pharmacies.
Our investigation also discusses other aspects of that industry, including these forces:
• Alliance Boots merging with Walgreens, and other mergers and acquisitions - explore the effects of takeovers, partnerships and other deals shaping that industry
• Parallel trade - activities, policies, challenges and effects
• Inventory management agreements, clawbacks, reimbursement and discounts
• Rise of specialty medicines, including biologics, complex generics, vaccines and biosimilars - opportunities for intermediaries, including cold chain distribution networks
• Actions against drug counterfeiting - security of pharmaceutical supply chains
• Changes to regulations and healthcare budgets - policies affecting trade.
That way you assess technological, economic, social and political questions, exploring news and outlooks for the pharmaceutical supply chain. You also analyse that industry's strengths, weaknesses, opportunities and threats.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Discover what the future holds, seeing what is likely to happen, finding how you can benefit.
Value of the overall pharma W&D market in 2019 - what revenue is possible?
Visiongain forecasts that the pharmaceutical wholesale and distribution industry will achieve revenues of $1,292 billion worldwide in 2019. That market continues to rise.
Wholesale and distribution services will experience steady revenue growth from 2015 to 2025, adapting to driving and restraining forces - changes, opportunities and threats. Find how high that industry's turnover can go, also seeing what influences revenues and profits.
So discover with our data revenue streams and opportunities for intermediaries in the pharma supply chain. You explore established, emerging and rising companies. Their market holds great potential from 2015 for investments, progress and expansion.
Ways World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025 helps
In our new analysis you gain the following knowledge to benefit your work and authority:
• World pharma W&D revenue to 2025 - discover that industry's overall sales potential
• 3 world-level submarkets' revenues to 2025 - investigate segments' potentials, finding the most promising places for developments, investments and sales
• 10 leading companies' revenues to 2025 - discover forecasts for leading players, seeing how they can develop, compete and succeed
• 11 national market forecasts to 2025 in the Americas, Europe and Asia - find the leading countries for revenues, demand and potential sales growth
• Activities of leading organisations - analyse participants' results, actions, capabilities, deals, mergers and acquisitions
• Competition and opportunities - explore what shapes that industry's future, assessing prospects for sustaining and developing business, helping you compete and succeed.
That report, by visiongain's in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.
Data found nowhere else - benefit your research, decisions, plans and authority
Our investigation gives independent analysis. There you receive discussions and predictions found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses and decisions, also saving time and getting recognition for commercial insight.
Our analysis costs only a tiny fraction of potential profits from your understanding and harnessing the pharma W&D market. See its growth potential and find what you could gain.
Forecasts for pharmaceutical supply - stay ahead by trying our analysis now
Our new study is for everyone analysing the supply of human medicines. In that work you explore results, trends, opportunities and revenue predictions, seeing what is possible. Stay ahead by getting that report here now.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100
Organisations Mentioned in the Report
AAH Pharmaceuticals
Admenta Italia
Alfresa Corporation
Alfresa Healthcare Corporation
Alfresa Holdings
Alfresa Medical Service Corporation
Alfresa Nikken Sangyo Corporation
Alfresa Pharma Corporation
Alfresa System Corporation
Alliance Boots
Alliance Healthcare
Alphega Network
AmerisourceBergen
Apokjeden AS
ARATA CORPORATION
Asociación Cooperativas Farmacéuticas (Acofarma)
ASTIS Co.
AstraZeneca
Athos Farma
Barr Pharmaceuticals
Bayer
Bristol-Myers Squibb
Brocacef Groep NV
Bundesverband des PharmazeutischenGrosshandel (PHAGRO)
Cardinal Foods
Cardinal Health
Cardinal Health China
CareFusion
Catalent Pharma Solutions
Celesio AG
Celesio UK
CERP BretagneNord
CERP Network
CERP Rouen
China Health Systems
China National Pharmaceutical Group
Chuo Unyu Co.
Cofares
Comifar
Comifar Group
CS YAKUHIN CO.
CVS Caremark
DEA
Dong Ying (Jiangsu) Pharmaceuticals Co.
DrogariasTamoio Network
Drug Trading Company
ERP Rhin Rhone Mediterranee
European Association of Euro-Pharmaceutical Companies (EAEPC)
European Court of Justice
European Pharmacy Network (EPN)
Express Scripts
Food and Drug Administration (US FDA)
GlaxoSmithKline (GSK)
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceuticals Corporation (GP Corp)
Hanshin Dispensing Pharmacy Holdings Co.
Healthcare Solutions Holding
Hefame
Institute for Pharmaeconomic Research (IPF)
Japanese Pharmaceutical Wholesalers Association
Kenzmedico Co.
Kinray
Kowa Pharmaceuticals Co.
Libra AG
Life Medicom Co.
LloydsPharmacy
McKesson
McQueary Brothers of Springfield
Medicaid
Medicare
Medicine Shoppe Canada
Medipal Holdings
Meisho Co.
MSD
Nakano Yakuhin Co.
National Development and Reform Commission (NDRC)
National Health Insurance (NHI)
National Health Service (NHS)
National Pharmaceutical Pricing Authority (NPPA)
Nomeco
Novation LLC
Odashima Limited
Oncology Therapeutics
Oncoprod
Panpharma
Pfercos Co.
Pfizer
PHOENIX Arzneiwarengroßhandlung Ges.m.b.H.
PHOENIX Farmacija d.d.
PHOENIX Group
PHOENIX Lékárenský velkoobchod, a.s.
PHOENIX Pharma d.o.o.
PHOENIX Pharma DOOEL
PHOENIX Pharma Polska Sp. z o.o.
PHOENIX Pharma S.A.S
PHOENIX Pharma Zrt.
PHOENIX Pharmahandel
PHOENIX Zdravotnícke zásobovanie
Polish Pharmaceutical Council (NRA)
Polska Grupa Farmaceutyczna, Torfarm
Premium Purchasing Partners LP
Profarma
Prosper
Protek
PSS World Medical
QINGDAO NESCO MEDICAL CO.
Ratiopharm
RYUYAKU CO.
S.D.Next Co.
Sanacorp
Sanki Clinical Link Co.
Sanki Corporation
Sanki Wellbe Co., Ltd. S-Care Mate Co.
Sanofi
Sandoz
Sanwa Kagaku Kenkyusho Co.
SEIWA SANGYO CO.
Shanghai Pharmaceuticals
Shikoku Alfresa Corporation
Shoyaku Co.
SIA International
SIA Tamro
SINOPHARM Group Co.
State Food and Drug Administration (SFDA)
SUZUKEN
Suzuken Iwate Co.
Suzuken Okinawa Yakuhin Co.
TAMPEI NAKATA CO.
Tamro AB
Tamro Eesti OÜ
Tamro Oyj
The Healthcare Distribution Management Association (HDMA)
Tokiwa Yakuhin Co
UAB Tamro
US Oncology Holdings
Walgreens
Walmart
Zuellig Pharma China
Share this article